Pacira Pharm Inc (PCRX) Stock Price, Quote & News

Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld c...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 813 553 6680

Website: www.pacira.com

Address:

5401 West Kennedy Boulevard, Suite 890, Tampa, United States

ZacksResearch Jan. 14 at 3:38 PM

$PCRX partners with LG Chem — paving the way for growth in Asia! This strategic move grants LG Chem exclusive rights to commercialize Exparel in select Asia-Pacific markets, opening new revenue channels for Pacira BioSciences through transfer pricing and royalties. Discover the full potential of this deal here 👉 https://www.zacks.com/stock/news/2817385/pcrx-lg-chem-partner-to-expand-exparel-reach-across-the-asia-pacific?cid=sm-stocktwits-2-2817385-body-28861&ADID=SYND_STOCKTWITS_TWEET_2_2817385_BODY_28861

0 · Reply

ZacksResearch Jan. 14 at 2:38 PM

Big international expansion move for $PCRX — and it’s all about growth beyond the U.S. Pacira BioSciences is partnering with LG Chem to expand Exparel across the Asia-Pacific region, unlocking royalties and new revenue channels to support international growth. See how this partnership could broaden Exparel’s reach 👉 https://www.zacks.com/stock/news/2817385/pcrx-lg-chem-partner-to-expand-exparel-reach-across-the-asia-pacific?cid=sm-stocktwits-2-2817385-teaser-28827&ADID=SYND_STOCKTWITS_TWEET_2_2817385_TEASER_28827

0 · Reply

A_Train1 Jan. 13 at 5:37 PM

$PCRX well it’s at least some news that they are doing something: https://www.nasdaq.com/articles/pacira-biosciences-signs-deal-lg-chem-commercialize-exparel-select-asia-pacific-markets

1 · Reply

ZacksResearch Jan. 12 at 4:52 PM

$PCRX dips 9.6% after missing Q4 revenue estimates Exparel sales up 5% from the year-ago quarter, but volume growth was partly offset by new partnerships Zilretta sales flat, missing expectations Iovera sales up 8% from the year-ago quarter, yet fell short of estimates Find out what’s next for PCRX 👉 https://www.zacks.com/stock/news/2815815/pcrx-stock-down-10-as-preliminary-q4-revenues-miss-estimates?cid=sm-stocktwits-2-2815815-body-28452&ADID=SYND_STOCKTWITS_TWEET_2_2815815_BODY_28452

0 · Reply

BEATOFtheMARKET Jan. 12 at 4:15 PM

$AMC $PCRX $ANIP $DX

0 · Reply

ZacksResearch Jan. 12 at 3:52 PM

$PCRX drops hard — revenue miss spooks the market Shares slid nearly 10% after preliminary Q4 revenues came in at $196.9M, missing estimates, even though Exparel sales topped forecasts — not enough to offset the headline miss. See what investors should focus on next 👉 https://www.zacks.com/stock/news/2815892/did-an-outdated-procedure-cause-rivians-20k-r1-vehicle-recall?cid=sm-stocktwits-2-2815892-teaser-28435&ADID=SYND_STOCKTWITS_TWEET_2_2815892_TEASER_28435

0 · Reply

BEATOFtheMARKET Jan. 11 at 10:58 PM

$AMC $PCRX $ANIP $DX 🔥 Cycle Trading Signal 🔥 app 🔥 with momentum trigger buy and pullback signal 🔥

0 · Reply

NakedDayTrader4 Jan. 10 at 2:29 PM

$PCRX still scratching my head to the reaction of $726.4mill revenue for 2025’. Per their last earnings release, where they lowered rev guidance, they projected $725MIL at bottom end of range and they’re above that. Not sure why this was such a surprise. Analysts projected more ? No idea why many stock prices are dictated by analyst projections instead of growth rates and cash flows.. sooo stooopid.

1 · Reply

NakedDayTrader4 Jan. 9 at 4:37 PM

$PCRX crushed again. Yikes

1 · Reply

OpenOutcrier Jan. 9 at 1:36 PM

$PCRX (-7.8% pre) Pacira BioSciences (PCRX) Shares Dip After Revenue Outlook Cut https://ooc.bz/l/89187

0 · Reply

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

Jan 8, 2026, 4:01 PM EST - 6 days ago

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Jan 7, 2026, 8:00 AM EST - 7 days ago

Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences

Dec 30, 2025, 10:41 AM EST - 15 days ago

DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

Dec 3, 2025, 8:00 AM EST - 6 weeks ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 26, 2025, 4:01 PM EST - 7 weeks ago

Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical

Nov 11, 2025, 8:00 AM EST - 2 months ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Nov 10, 2025, 8:09 PM EST - 2 months ago

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

Nov 7, 2025, 6:16 AM EST - 2 months ago

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 2 months ago

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

Nov 5, 2025, 8:00 AM EST - 2 months ago

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Nov 4, 2025, 7:00 AM EST - 2 months ago

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

Oct 20, 2025, 4:01 PM EDT - 3 months ago

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

Aug 6, 2025, 2:42 AM EDT - 5 months ago

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:00 PM EDT - 5 months ago

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Jul 24, 2025, 8:00 AM EDT - 6 months ago

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025

Jul 16, 2025, 8:40 AM EDT - 6 months ago

Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit

Jun 17, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 7 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect

Jun 1, 2025, 10:00 AM EDT - 8 months ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out

May 20, 2025, 10:00 AM EDT - 8 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect

May 13, 2025, 10:35 AM EDT - 8 months ago

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

May 13, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out

May 11, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

May 8, 2025, 10:31 PM EDT - 8 months ago

Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:00 PM EDT - 8 months ago

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 8, 2025, 10:00 AM EDT - 8 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 6, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect

May 4, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

May 2, 2025, 8:00 AM EDT - 9 months ago

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 1, 2025, 10:00 AM EDT - 9 months ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation

Apr 29, 2025, 8:00 AM EDT - 9 months ago

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Apr 28, 2025, 8:00 AM EDT - 9 months ago

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Apr 24, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out

ZacksResearch Jan. 14 at 3:38 PM

0 · Reply

ZacksResearch Jan. 14 at 2:38 PM

0 · Reply

A_Train1 Jan. 13 at 5:37 PM

$PCRX well it’s at least some news that they are doing something: https://www.nasdaq.com/articles/pacira-biosciences-signs-deal-lg-chem-commercialize-exparel-select-asia-pacific-markets

1 · Reply

ZacksResearch Jan. 12 at 4:52 PM

0 · Reply

BEATOFtheMARKET Jan. 12 at 4:15 PM

$AMC $PCRX $ANIP $DX

0 · Reply

ZacksResearch Jan. 12 at 3:52 PM

0 · Reply

BEATOFtheMARKET Jan. 11 at 10:58 PM

$AMC $PCRX $ANIP $DX 🔥 Cycle Trading Signal 🔥 app 🔥 with momentum trigger buy and pullback signal 🔥

0 · Reply

NakedDayTrader4 Jan. 10 at 2:29 PM

1 · Reply

NakedDayTrader4 Jan. 9 at 4:37 PM

$PCRX crushed again. Yikes

1 · Reply

OpenOutcrier Jan. 9 at 1:36 PM

$PCRX (-7.8% pre) Pacira BioSciences (PCRX) Shares Dip After Revenue Outlook Cut https://ooc.bz/l/89187

0 · Reply

Maestro60 Jan. 9 at 12:13 PM

$PCRX https://www.gurufocus.com/news/4103762/pacira-biosciences-pcrx-rating-reiterated-as-buy-by-hc-wainwright-co-pcrx-stock-news

0 · Reply

DonCorleone77 Jan. 9 at 12:20 AM

$OPAD $OPEN $RKT $PCRX $AEHR AFTER-HOURS MOVERS Higher After Trump Instructs "Representatives" to Buy $200B of Mortgage Bonds: - Offerpad Solutions (OPAD) up 54.6% - Opendoor Technologies (OPEN) up 11.8% - Rocket Companies (RKT) up 6.3% - UWM Holdings (UWMC) up 6.2% Currently Lower After Earnings: - Pacira (PCRX) down 9.7% - WD-40 (WDFC) down 8.6% - AEHR Test Systems (AEHR) down 5.7% Currently Also Lower: - AXT Inc. (AXTI) down 22.5% after cutting its Q4 guidance - Olin (OLN) down 8.0% after updating its Q4 outlook, - General Motors (GM) down 1.7% after saying it expects an additional $6B in charges related to a review of EV capacity and investments

0 · Reply

BillionerOfKing Jan. 5 at 1:07 PM

$PCRX Current Stock Price: $24.47 Contracts to trade: $25 PCRX Jan 16 2026 Call Entry: $1.26 Exit: $2.40 ROI: 90% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

NakedDayTrader4 Jan. 2 at 6:38 PM

$PCRX crushed

1 · Reply

VisionaryVortex Dec. 26 at 1:17 PM

$PCRX The environment increasingly favors disciplined operators instead of aggressive storytellers. Improving execution cadence across quarters would alter sentiment materially. Demonstrated durability would lengthen investor time horizons. Investors will likely reward proof above promises.

0 · Reply

Estimize Dec. 22 at 2:00 PM

Wall St is expecting 0.90 EPS for $PCRX Q4 [Reporting 02/19 AMC] http://www.estimize.com/intro/pcrx?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser Dec. 15 at 11:38 AM

$PCRX RSI: 89.13, MACD: 0.6289 Vol: 0.88, MA20: 24.11, MA50: 23.16 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

tcave Dec. 9 at 8:52 PM

$PCRX 2yr long inverse head/shoulders pattern on the weekly. Short ratio of 11.58 days according to finviz.

0 · Reply

JarvisFlow Dec. 9 at 4:05 PM

Barclays has adjusted their stance on Pacira BioSciences ( $PCRX ), setting the rating to Equal-Weight with a target price of 27.

0 · Reply

jimbecker Dec. 9 at 2:36 PM

$PCRX Trying to break out of a strong double bottom pattern

0 · Reply

ZacksResearch Dec. 3 at 3:26 PM

$PCRX's iovera system shows promise in facet-mediated CLBP treatment! Pilot study reveals iovera's cryoneurolysis outperforms RFA with significantly lower pain scores and reduced disability over 360 days. Plus, no treatment-related adverse events reported. Discover the full impact of these findings here 👉 https://www.zacks.com/stock/news/2798991/pcrxs-iovera-outperforms-rfa-therapy-in-pilot-study-for-low-back-pain?cid=sm-stocktwits-2-2798991-body-23249&ADID=SYND_STOCKTWITS_TWEET_2_2798991_BODY_23249

0 · Reply

ZacksResearch Dec. 3 at 2:26 PM

Game-changer alert for $PCRX Iovera just posted stronger, longer-lasting relief than RFA in a pilot CLBP study — and that tissue-sparing angle could be a real edge in spine care. See what this could mean for the future of pain management 👉 https://www.zacks.com/stock/news/2798991/pcrxs-iovera-outperforms-rfa-therapy-in-pilot-study-for-low-back-pain?cid=sm-stocktwits-2-2798991-teaser-23248&ADID=SYND_STOCKTWITS_TWEET_2_2798991_TEASER_23248

0 · Reply

Market Cap	986.47M
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
EPS (ttm)	N/A
PE Ratio	11.59
Forward PE	10.16
Profit Margin	-14.20%
Debt to Equity Ratio	0.52

Volume	1,030,341
Avg Vol	854,850
Day's Range	N/A - N/A
Shares Out	43.02M
Stochastic %K	1%
Beta	0.22
Analysts	Sell
Price Target	$29.71